Description

This advanced sexual wellness capsule combines five compounds with complementary mechanisms addressing the central nervous system, hormonal, vascular, and psychological dimensions of sexual function. PT-141 (Bremelanotide) is a melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it the only centrally-acting approved sexual desire medication. Oxytocin is the endogenous neuropeptide associated with bonding, trust, and arousal, with demonstrated effects on sexual motivation and partner bonding. N-Acetyl L-Tyrosine (NALT) provides a bioavailable precursor to dopamine and norepinephrine, supporting the catecholaminergic signaling that underlies sexual motivation and reward. Kisspeptin is a hypothalamic neuropeptide that stimulates GnRH (gonadotropin-releasing hormone) release, which drives downstream LH and FSH production and ultimately sex hormone synthesis. VIP (Vasoactive Intestinal Peptide) is a neuropeptide with vasodilatory and neuromodulatory properties that supports genital blood flow and arousal responses. Together, these five compounds provide a comprehensive approach to sexual wellness through central desire (PT-141), bonding (Oxytocin), dopaminergic motivation (NALT), hormonal optimization (Kisspeptin), and vascular support (VIP).

Key Characteristics

Investigated Benefits

* Benefits based on preclinical/animal research unless otherwise noted.